Among all blood cancers, the highest rates of SHP2 gain-of-function mutations occur in juvenile myelomonocytic leukemia, with leukemogenesis driven by SHP2 variants in up to 42% of these children (source: COSMIC database, March 2021). Here, PTPN11 is linked to juvenile myelomonocytic leukemia.